Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul-Aug;39(4):2311-2319.
doi: 10.21873/invivo.14027.

Impact of Adjuvant Chemotherapy Following Neoadjuvant Concurrent Chemoradiotherapy and Total Mesorectal Excision in Rectal Cancer

Yu-Shih Liu  1 , Jen-Kou Lin  2 , Tzu-Chen Lin  2 , Wei-Shone Chen  2   3 , Shung-Haur Yang  2   3 , Huann-Shenn Wang  2 , Shih-Ching Chang  2   3 , Yuan-Tzu Lan  2   3 , Chun-Chi Lin  2   3 , Hung-Hsin Lin  2   3 , Jeng-Kai Jiang  2   3
Affiliations

Impact of Adjuvant Chemotherapy Following Neoadjuvant Concurrent Chemoradiotherapy and Total Mesorectal Excision in Rectal Cancer

Yu-Shih Liu et al. In Vivo. 2025 Jul-Aug.

Abstract

Background/aim: This study investigated the efficacy of adjuvant chemotherapy (ACT) after total mesorectal excision (TME) for rectal cancer in patients who responded well to neoadjuvant concurrent chemoradiotherapy (nCCRT).

Patients and methods: This retrospective study included patients with rectal cancer treated at Taipei Veterans General Hospital (2009-2017). Among 302 patients who underwent nCCRT and TME, 178 good responders [pathologic complete response (pCR), pT1, or pT2] were analyzed. Patients were grouped based on ACT administration. Primary outcomes included disease-free survival (DFS) and recurrence. Kaplan-Meier survival analysis and Cox proportional hazards regression were used to assess ACT efficacy.

Results: The ACT group (n=96) had poorer baseline disease characteristics, including higher initial clinical T and N stages. However, recurrence rates did not differ significantly between ACT and non-ACT groups (23.2% vs. 17.7%, p=0.271). DFS curves showed no significant difference between ACT and non-ACT groups (p=0.360). Multivariable analysis confirmed that ACT was not significantly associated with DFS [adjusted hazard ratio (aHR)=0.76, 95% confidence interval (CI)=0.37-1.59]. However, the advanced surgical pT stage (pT3-pT4) was an independent predictor of recurrence (aHR=3.24, 95%CI=1.01-10.38, p=0.047).

Conclusion: The role of ACT remains inconclusive after TME for rectal cancer in patients who respond well to nCCRT. Surgical pT stage, particularly pT3 and pT4, remain a significant predictor of recurrence, emphasizing its importance in risk stratification.

Keywords: Rectal cancer; adjuvant chemotherapy (ACT); neoadjuvant concurrent chemoradiotherapy (nCCRT); total mesorectal excision (TME).

PubMed Disclaimer

Conflict of interest statement

All the Authors have no conflicts of interest to declare in relation to this manuscript.

Figures

Figure 1
Figure 1
Flowchart of the patient selection process.
Figure 2
Figure 2
Flowchart of the patient selection process.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;327(8496):1479–1482. doi: 10.1016/s0140-6736(86)91510-2. - DOI - PubMed
    1. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264 (11):1444–50. - PubMed
    1. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA, Twito DI, Morton RF, Veeder MH, Witzig TE, Cha S, Vidyarthi SC. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709–715. doi: 10.1056/NEJM199103143241101. - DOI - PubMed
    1. Wee CW, Kang HC, Wu HG, Chie EK, Choi N, Park JM, Kim JI, Huang CM, Wang JY, Ng SY, Goodman KA. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in rectal cancer treated with neoadjuvant concurrent chemoradiation: a meta-analysis and pooled-analysis of acute toxicity. Japanese J Clin Oncol. 2018;48(5):458–466. doi: 10.1093/jjco/hyy029. - DOI - PubMed
    1. Parulekar W, de Marsh RW, Wong R, Mendenhall W, Davey P, Zlotecki R, Berry S, Rout WR, Bjarnason GA. Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer. Int J Radiat Oncol Biol Phys. 2004;58(5):1487–1495. doi: 10.1016/j.ijrobp.2003.09.073. - DOI - PubMed

LinkOut - more resources